Drug Trial Radar · NCT07604766
An Extension Study to Assess the Efficacy of Rina-S Compared to Treatment of Investigator's Choice in Participants With Platinum Resistant Ovarian Cancer in China
Last checked: Nov 19, 2026Latest source record: Nov 3, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
82
Planned (sponsor's estimate)
Start
Jun 26, 2026
Primary completion
Sep 2027
Study completion Dec 2028
Sponsor
- Lead sponsor
- GenmabIndustry
- Sponsor type
- Industry
- First posted
- May 22, 2026
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- Female only, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this Chinese extension study is to compare how well Rina-S works against platinum-resistant ovarian cancer compared to chemotherapy drugs that are already approved and used for platinum-resistant ovarian cancer. Treatment in this study could be Rina-S or it could be 1 of 4 indicated chemotherapy agents that are considered standard medical care. There is an equal (50:50) chance of getting Rina-S or an approved chemotherapy agent as treatment in this study. No one will know what treatment they are assigned to until the first dose. All participants will receive active drug; no one will be given placebo. This study is an extension study of the protocol GCT1184-02 (NCT06619236).
Conditions
- Platinum-resistant Ovarian Cancer
Interventions
Rina-SDrug
Intravenous (IV) infusion
PaclitaxelDrug
IV infusion
TopotecanDrug
IV infusion
Pegylated liposomal doxorubicin (PLD)Drug
IV infusion
GemcitabineDrug
IV infusion
Primary outcomes
What the sponsor says the trial is designed to measure.
- Progression-Free Survival (PFS)Time frame: Up to approximately 16 months
Locations
17 sites in 1 country. Site status is shown where the registry gives one.
The First Hospital of Jilin University
Changchun, China · Recruiting
Hunan Cancer Hospital
Changsha, China · Recruiting
West China Second University Hospital, Sichuan University
Chengdu, China · Recruiting
Chongqing University Cancer Hospital - Chongqing Cancer Hospital
Chongqing, China · Recruiting
Sun Yat-Sen Memorial Hospital
Guangzhou, China · Recruiting
Sun Yat-Sen University Cancer Center
Guangzhou, China · Recruiting
Zhejiang Cancer Hospital
Hangzhou, China · Recruiting
Harbin Medical University Cancer Hospital
Harbin, China · Recruiting
Shandong First Medical University Affiliated Tumor Hospital
Jinan, China · Recruiting
Nanjing Drum Tower Hospital (The Affiliated Hospital of Nanjing University Medical School)
Nanjing, China · Recruiting
Fudan University Shanghai Cancer Hospital
Shanghai, China · Recruiting
Obstetrics & Gynecology Hospital of Fudan University
Shanghai, China · Recruiting
Liaoning Cancer Hospital
Shenyang, China · Recruiting
Shanxi Cancer Hospital
Taiyuan, China · Recruiting
Tianjin Medical University Cancer Institute & Hospital
Tianjin, China · Recruiting
The First Affiliated Hospital of Xi'an Jiaotong University
Xi'an, China · Recruiting
Henan Cancer Hospital
Zhengzhou, China · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.